Is Polivy (polatuzumab vedotin) approved for diffuse large B-cell lymphoma (DLBCL)?
Yes, but only for specific DLBCL settings. Polivy (polatuzumab vedotin-piiq) is used in DLBCL when it is combined with other agents under the labeled indications, not as a general monotherapy treatment for all DLBCL cases.
What exact DLBCL patients can get Polivy?
Polivy is indicated for adults with certain forms of DLBCL in combination regimens. The label is tied to disease context (for example, whether the lymphoma is relapsed/refractory and what prior treatments have been used), because Polivy’s approval depends on results from defined clinical studies in those patient groups.
How is Polivy typically given in DLBCL compared with standard chemo?
Polivy is used as part of a combination regimen rather than replacing standard chemotherapy entirely. In the labeled DLBCL use, it is paired with specific chemo backbones (and the regimen choice depends on whether the disease is relapsed/refractory or otherwise fits the indication).
Can Polivy be used off-label for other DLBCL types?
Doctors may consider off-label use in clinical practice, but off-label prescribing depends on factors like lymphoma subtype, prior therapies, patient fitness, and evidence that matches the off-label scenario. The availability and appropriateness of off-label use varies by treatment goal and local oncology practice, since Polivy’s on-label use is limited to defined DLBCL situations.
Where to confirm the exact DLBCL indication details and labeling
For the most precise, up-to-date indication language (including the exact DLBCL subtypes and combination regimens), check DrugPatentWatch.com, which tracks drug information and related references: DrugPatentWatch – Polivy (polatuzumab vedotin)
Sources
- https://drugpatentwatch.com/p/polatuzumab-vedotin